menu
    • menu
    [{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Not Applicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seika Pharma \/ Eisai"},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Switzerland","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Switzerland \/ Newron Pharmaceuticals"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Newron Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"CSL","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Pharmanovia"}]

    Find Clinical Drug Pipeline Developments & Deals for Safinamide Mesylate

    Menu

    Safinamide Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSL

                            Australia arrow
                            PharmaVenue
                            Not Confirmed

                            CSL

                            Australia arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease

                            Details : Pharmanovia will take over rights from CSL and will be responsible for all commercial and regulatory activities of Xadago (safinamide), for adult patients with idiopathic Parkinson's disease.

                            Brand Name : Xadago

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 07, 2024

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Newron Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Newron Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Zambon Group SpA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia

                            Details : Under the agreement, Newron and Zambon have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease.

                            Brand Name : Xadago

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Zambon Group SpA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zambon Switzerland

                            Switzerland arrow
                            PharmaVenue
                            Not Confirmed

                            Zambon Switzerland

                            Switzerland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Newron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson’s Disease Patien...

                            Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.

                            Brand Name : Xadago

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 12, 2021

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Newron Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meiji Seika Pharma

                            Japan arrow
                            PharmaVenue
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eisai to Take Over Manufacturing and Marketing Approval for Equfina® 50 Mg Tablets (safinamide Mesilate)INn J...

                            Details : Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.

                            Brand Name : Equfina

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 07, 2020

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eisai

                            Japan arrow
                            PharmaVenue
                            Not Confirmed

                            Eisai

                            Japan arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eisai’s Equfina receives South Korean marketing approval to treat Parkinson’s disease

                            Details : The marketing authorization application for safinamide in South Korea was submitted in July 2019, and through the approval of this application, South Korea became the first country in Asia outside of Japan to grant marketing approval for safinamide.

                            Brand Name : Equfina

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 25, 2020

                            Lead Product(s) : Safinamide Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth